

# Bernard E Weissman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3270392/publications.pdf>

Version: 2024-02-01

28  
papers

2,102  
citations

361413

20  
h-index

526287

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2641  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. <i>Cancer Research</i> , 2003, 63, 560-6.	0.9	282
2	Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. <i>Journal of Cellular Physiology</i> , 2001, 186, 136-145.	4.1	172
3	Dual loss of the <sc>SWI</sc>/<sc>SNF</sc> complex <sc>ATPases SMARCA4</sc>/<sc>BRG1</sc> and <sc>SMARCA2</sc>/<sc>BRM</sc> is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2016, 238, 389-400.	4.5	169
4	Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. <i>Oncogene</i> , 2001, 20, 3258-3265.	5.9	157
5	Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. <i>Oncogene</i> , 2002, 21, 1196-1207.	5.9	141
6	NRF2 Activation in Cancer: From DNA to Protein. <i>Cancer Research</i> , 2019, 79, 889-898.	0.9	140
7	Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. <i>Journal of Cellular Physiology</i> , 2001, 186, 136-145.	4.1	126
8	BRG1/SMARCA4 Inactivation Promotes Non-“Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization. <i>Cancer Research</i> , 2014, 74, 6486-6498.	0.9	104
9	Compensation of BRG-1 Function by Brm. <i>Journal of Biological Chemistry</i> , 2002, 277, 4782-4789.	3.4	97
10	Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. <i>Oncogene</i> , 1999, 18, 7559-7565.	5.9	84
11	Small-Cell Carcinoma of the Ovary, Hypercalcaemic Type-“Genetics, New Treatment Targets, and Current Management Guidelines. <i>Clinical Cancer Research</i> , 2020, 26, 3908-3917.	7.0	82
12	The BRG-1 Subunit of the SWI/SNF Complex Regulates CD44 Expression. <i>Journal of Biological Chemistry</i> , 2001, 276, 9273-9278.	3.4	80
13	The histone methyltransferase <sc>EZH2</sc> is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2017, 242, 371-383.	4.5	78
14	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcaemic Type (SCCOHT) through Multikinase Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 1932-1943.	7.0	51
15	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcaemic Type. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2767-2779.	4.1	50
16	The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. <i>PLoS ONE</i> , 2020, 15, e0235705.	2.5	44
17	The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. <i>Scientific Reports</i> , 2018, 8, 15304.	3.3	43
18	SNF5/INI1 Deficiency Redefines Chromatin Remodeling Complex Composition during Tumor Development. <i>Molecular Cancer Research</i> , 2014, 12, 1574-1585.	3.4	31

#	ARTICLE	IF	CITATIONS
19	Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 375-391.	2.4	30
20	Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma. <i>Molecular Cancer Research</i> , 2020, 18, 1777-1788.	3.4	24
21	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	7.0	21
22	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2021, 160, 568-578.	1.4	21
23	Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism. <i>ELife</i> , 2020, 9, .	6.0	19
24	A cytoskeletal function for PBRM1 reading methylated microtubules. <i>Science Advances</i> , 2021, 7, .	10.3	17
25	A conditional mouse expressing an activating mutation in <i>NRF2</i> displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue. <i>Journal of Pathology</i> , 2020, 252, 125-137.	4.5	16
26	Differences in the microbial profiles of early stage endometrial cancers between Black and White women. <i>Gynecologic Oncology</i> , 2022, , .	1.4	11
27	TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. <i>Oncogene</i> , 2022, 41, 3423-3432.	5.9	7
28	High Frequency of Ovarian Cyst Development in <i>Vhl;Snf5</i> Mice. <i>American Journal of Pathology</i> , 2018, 188, 1510-1516.	3.8	0